Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma  

Oleh:

Cheson, Bruce D. ; Leonard, John P.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 359 no. 06 (Aug. 2008), page 613.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2008.04 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Non-Hodgkin's lymphoma is the most common hematologic cancer in adults, with more than 66,000 incident cases anticipated in the United States in 2008.1 Approximately 85% of non-Hodgkin's lymphomas in adults are of B cell origin.2 Some B-cell non-Hodgkin's lymphomas are indolent, or slow-growing, yet incurable. In contrast, others are aggressive or very aggressive, and may be rapidly fatal, yet are often curable. There has been a revolution in the treatment of B-cell non-Hodgkin's lymphomas, owing largely to the availability of therapeutic monoclonal antibodies. The concept that antibodies might be effective for the treatment of cancers originated more than a century . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali